Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2017 May 17

PMID 28508264

Citations 5

Authors

Caroline Goussen

Steve Simoneau

Soline Berend

Christine Jehan-Kimmel

Anne Bellon

Celine Ducloux

Bruno You

Philippe Paolantonacci

Monique Ollivier

Ludovic Burlot

Sami Chtourou

Benoit Flan

Affiliations

Soon will be listed here.

Abstract

Background: A highly purified 10% liquid intravenous immunoglobulin, IQYMUNE, has been developed using an innovative manufacturing process including an affinity chromatography step for the removal of anti-A and anti-B hemagglutinins.

Objectives: The pathogen (viruses and prions) clearance efficacy of the manufacturing process and its robustness for critical steps were investigated.

Methods: The manufacturing process of IQYMUNE includes two dedicated complementary virus reduction steps: solvent/detergent (S/D) treatment and 20 nm nanofiltration as well as two contributing steps, namely caprylic acid fractionation and anion-exchange chromatography. The clearance capacity and robustness of these steps were evaluated with a wide range of viruses (enveloped and non-enveloped) and with a model of human transmissible spongiform encephalopathies (TSEs).

Results: The IQYMUNE manufacturing process demonstrated a high and robust virus removal capacity with global reduction factors (RFs) of relevant and model viruses: ≥14.8 log for human immunodeficiency virus type 1 (HIV-1), ≥16.9 log for bovine viral diarrhoea virus (BVDV)/Sindbis virus, ≥15.7 log for pseudorabies virus (PRV), ≥12.8 log for encephalomyocarditis virus (EMCV) and 11.0 log for porcine parvovirus (PPV). The process also exhibited a high removal capacity for the TSE agent with an overall RF of ≥12.9 log due to the complementary actions of the caprylic acid fractionation, anion-exchange chromatography and nanofiltration steps.

Conclusion: Data from virus and prion clearance studies fully support the high safety profile of IQYMUNE, with a minimal reduction of 11 log for the smallest and most resistant non-enveloped virus, PPV, and more than 12 log for the TSE agent.

Citing Articles

Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.

Burnouf T, Gathof B, Bloch E, Bazin R, De Angelis V, Patidar G Transfus Med Rev. 2022; 36(3):125-132.

PMID: 35879213 PMC: 9183240. DOI: 10.1016/j.tmrv.2022.06.001.

Can the administration of platelet lysates to the brain help treat neurological disorders?.

Nebie O, Buee L, Blum D, Burnouf T Cell Mol Life Sci. 2022; 79(7):379.

PMID: 35750991 PMC: 9243829. DOI: 10.1007/s00018-022-04397-w.

Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in Australia.

McManus H, Seed C, Hoad V, Kiely P, Kaldor J, Styles C Vox Sang. 2022; 117(8):1016-1026.

PMID: 35609012 PMC: 9544957. DOI: 10.1111/vox.13290.

Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.

Cheng J, Wu Y, Wang C, Wu S, Hong C, Chan K Blood Transfus. 2021; 19(6):467-478.

PMID: 34369872 PMC: 8580789. DOI: 10.2450/2021.0159-21.

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.

Shebl A, Gabriel S, Van Dinther K, Hubsch A, Lawo J, Hoefferer L Transfusion. 2020; 60(6):1278-1286.

PMID: 32410287 PMC: 7383922. DOI: 10.1111/trf.15846.

References

Korneyeva M, Hotta J, Lebing W, ROSENTHAL R, Franks L, Petteway Jr S . Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals. 2002; 30(2):153-62. DOI: 10.1006/biol.2002.0334. View

Flan B, Arrabal S . Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol. 2007; 14(1):51-62. DOI: 10.1016/j.tracli.2007.04.008. View

Johnston A, Uren E, Johnstone D, Wu J . Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies. Biologicals. 2003; 31(3):213-21. DOI: 10.1016/s1045-1056(03)00062-9. View

Borovec S, Broumis C, Adcock W, Fang R, Uren E . Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat. Biologicals. 1999; 26(3):237-44. DOI: 10.1006/biol.1998.0146. View

Bellon A, Comoy E, Simoneau S, Mornac S, Dehen C, Perrin A . Decontamination of prions in a plasma product manufacturing environment. Transfusion. 2013; 54(4):1028-36. DOI: 10.1111/trf.12381. View

Sriaroon P, Ballow M . Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin North Am. 2015; 35(4):713-30. DOI: 10.1016/j.iac.2015.07.006. View

Lundblad J, Seng R . Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang. 1991; 60(2):75-81. DOI: 10.1111/j.1423-0410.1991.tb00878.x. View

Hartung H, Mouthon L, Ahmed R, Jordan S, Laupland K, Jolles S . Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009; 158 Suppl 1:23-33. PMC: 2801038. DOI: 10.1111/j.1365-2249.2009.04024.x. View

Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A . Scrapie removal using Planova virus removal filters. Biologicals. 2001; 29(1):17-25. DOI: 10.1006/biol.2001.0269. View

10.

Dichtelmuller H, Biesert L, Fabbrizzi F, Gajardo R, Groner A, von Hoegen I . Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion. 2009; 49(9):1931-43. PMC: 7187780. DOI: 10.1111/j.1537-2995.2009.02222.x. View

11.

Foster P, Griffin B, Bienek C, McIntosh R, MacGREGOR I, Somerville R . Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang. 2004; 86(2):92-9. DOI: 10.1111/j.0042-9007.2004.00403.x. View

12.

FINNEY D . The median lethal dose and its estimation. Arch Toxicol. 1985; 56(4):215-8. DOI: 10.1007/BF00295156. View

13.

Hellstern P, Solheim B . The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. Transfus Med Hemother. 2011; 38(1):65-70. PMC: 3132981. DOI: 10.1159/000323552. View

14.

Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C . Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals. 2003; 31(3):181-5. DOI: 10.1016/s1045-1056(03)00037-x. View

15.

Burnouf T . Chromatographic removal of viruses from plasma derivatives. Dev Biol Stand. 1993; 81:199-209. View

16.

Trejo S, Hotta J, Lebing W, Stenland C, Storms R, Lee D . Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang. 2003; 84(3):176-87. DOI: 10.1046/j.1423-0410.2003.00279.x. View

17.

Lunemann J, Quast I, Dalakas M . Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2015; 13(1):34-46. PMC: 4720677. DOI: 10.1007/s13311-015-0391-5. View

18.

Horowitz B, Prince A, HOROWITZ M, Watklevicz C . Viral safety of solvent-detergent treated blood products. Dev Biol Stand. 1993; 81:147-61. View

19.

Tellier Z . Intravenous immunogloblins: myth and reality. Isr Med Assoc J. 2005; 7(12):762-7. View

20.

Yang H, Gregori L, Asher D, Epstein J, Anderson S . Risk assessment for transmission of variant Creutzfeldt-Jakob disease by transfusion of red blood cells in the United States. Transfusion. 2014; 54(9):2194-201. DOI: 10.1111/trf.12637. View